This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
by Ekta Bagri
ADMA's surging Asceniv demand and bold revenue forecasts set it apart in the competitive plasma therapies space.
ADMANegative Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Top Analyst Reports for JPMorgan, Novartis & AT&T
by Mark Vickery
JPM's strong NII outlook, NVS's blockbuster pipeline, and T's wireless momentum anchor today's top analyst picks.
JPMPositive Net Change NEEPositive Net Change NVSPositive Net Change TNegative Net Change JCINegative Net Change APHNegative Net Change UTMDPositive Net Change PPIHNegative Net Change
communications finance industrial-products medical pharmaceuticals
Can Hims Recover after Novo Nordisk Diss?
by David Bartosiak
Hims shares tumbled after Novo Nordisk canceled its partnership. Can the stock recover?
HIMSNegative Net Change
pharmaceuticals stock-performance
MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal
by Zacks Equity Research
Merck's Winrevair meets goal in a phase III study in newly diagnosed PAH patients, showing strong efficacy.
JNJPositive Net Change MRKPositive Net Change UTHRPositive Net Change EXELNegative Net Change
pharmaceuticals
CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication
by Zacks Equity Research
CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.
NVOPositive Net Change BAYRYPositive Net Change AGENPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers?
by Ahan Chakraborty
NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy, hitting patient access and market share plans.
NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change HIMSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Pfizer to Face Several Headwinds: Can It Successfully Navigate Them?
by Kinjel Shah
PFE faces a decline in COVID revenues, LOE pressure and IRA impacts but rising EPS estimates offer a glimmer of resilience.
JNJPositive Net Change PFEPositive Net Change MRKPositive Net Change LLYNegative Net Change
pharmaceuticals
Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?
by Kinjel Shah
SNY trades below key moving averages but strong Dupixent growth, pipeline wins and rising estimates may keep bulls invested.
REGNPositive Net Change SNYPositive Net Change AZNPositive Net Change MRKPositive Net Change
pharmaceuticals
EXEL Stock Rises on Positive Data From Colorectal Cancer Study
by Zacks Equity Research
EXEL jumps 7.4% as STELLAR-303 trial hits key survival goal in colorectal cancer, boosting hopes for an approval of zanzalintinib.
BMYPositive Net Change MRKPositive Net Change EXELNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer
by Zacks Equity Research
FDA expands AstraZeneca's Datroway label, making it the first TROP2-directed lung cancer therapy approved in the United States.
AZNPositive Net Change AGENPositive Net Change IMCRPositive Net Change
biotechs medical pharmaceuticals
Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?
by Sundeep Ganoria
ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost top-line growth.
AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
Top 3 Earnings Growth Stocks for Investment
by Tirthankar Chakraborty
AEM, ATR, and VICI stand out with rising earnings forecasts and solid growth, pointing to bullish investor potential.
AEMNegative Net Change ATRPositive Net Change VICIPositive Net Change
earnings gold pharmaceuticals reit
HIMS Stock Crashes 30% in a Day: Time to Buy the Dip?
by Ethan Feller
Hims & Hers stock crashes 30% on Monday after news of Novo Nordisk ending their partnership. Is HIMS now a compelling stock to buy?
NVOPositive Net Change LLYNegative Net Change HIMSNegative Net Change
medical pharmaceuticals
SNY Gets CHMP Nod for Expanded Use of Sarclisa in Multiple Myeloma
by Zacks Equity Research
Sanofi earns CHMP backing to expand Sarclisa's use for newly diagnosed multiple myeloma patients eligible for transplant.
SNYPositive Net Change BMYPositive Net Change EXELNegative Net Change AMRNPositive Net Change
pharmaceuticals
NVO Reports New Positive Phase III Data on Mim8 in Hemophilia A
by Zacks Equity Research
Novo Nordisk's Mim8 shows strong safety and patient preference in the phase IIIb hemophilia A study switching from Hemlibra to Mim8.
RHHBYPositive Net Change NVOPositive Net Change BAYRYPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Extends INCY's Application for Opzelura Label Expansion
by Zacks Equity Research
FDA extends review of Incyte's ruxolitinib cream for children with atopic dermatitis, delaying decision to September 2025.
GSKPositive Net Change BAYRYPositive Net Change INCYPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?
by Kinjel Shah
JNJ stock added $15B in market value in six months as new drug launches offset MedTech and Stelara headwinds.
JNJPositive Net Change AMGNPositive Net Change TEVANegative Net Change KVUEPositive Net Change
pharmaceuticals
J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications
by Zacks Equity Research
JNJ wins CHMP backing for Darzalex and Imbruvica in new blood cancer uses, paving the way for first-in-class approvals.
JNJPositive Net Change ABBVPositive Net Change AGENPositive Net Change IMCRPositive Net Change
biotechs medical pharmaceuticals
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
by Zacks Equity Research
CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.
BMYPositive Net Change BNTXPositive Net Change CVACNegative Net Change IMCRPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
by Ekta Bagri
Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.
BMYPositive Net Change PFEPositive Net Change
biotechnology biotechs cancer medical pharmaceuticals
Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
by Zacks Equity Research
SNY and REGN's Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the drug.
REGNPositive Net Change SNYPositive Net Change EXELNegative Net Change AMRNPositive Net Change
pharmaceuticals
LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet?
by Kinjel Shah
LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.
NVOPositive Net Change LLYNegative Net Change ABBVPositive Net Change
pharmaceuticals
FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention
by Zacks Equity Research
GILD wins FDA approval for Yeztugo, the first and only twice-yearly injectable PrEP for HIV prevention in the United States.
GSKPositive Net Change NVSPositive Net Change GILDPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?
by Ahan Chakraborty
LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.
SNYPositive Net Change NVOPositive Net Change LLYNegative Net Change VERVPositive Net Change
biotechnology biotechs gene-editing gene-therapy medical oncology-screening pharmaceuticals
Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?
by Kinjel Shah
PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance.
AZNPositive Net Change BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change
pharmaceuticals